新冠肺炎预防2号方联合胸腺法新对晚期非小细胞肺癌化疗后免疫功能的影响

Effect of No.2 COVID-19 Prevention Formula Combined with Thymalfasin on Immune Function of Advanced Non-Small Cell Lung Cancer after Chemotherapy

目的探讨新冠肺炎预防2号方联合胸腺法新对晚期非小细胞肺癌(non-small cell lung cancer,NSCLC)化疗后免疫功能及生活质量的影响。方法选取2020年1月1日—2020年3月15日该院收治的晚期NSCLC患者为研究对象,根据随机数字表随机分为观察组和对照组,每组各50例。两组患者均采用多西他赛联合顺铂进行化疗,对照组另给予胸腺法新皮下注射,观察组在对照组基础上另加新冠肺炎预防2号方口服治疗。1个化疗周期为21 d,连续治疗3个周期。比较两组治疗前后T细胞亚群、体液免疫指标、淋巴细胞水平及生活质量改变情况。结果治疗后,观察组CD_(4)^(+)水平和CD_(4)^(+)/CD_(8)^(+)比值高于对照组,差异有统计学意义(P<0.05);治疗后,两组IgG、IgA、IgM水平以及淋巴细胞百分率、淋巴细胞绝对值无明显差异(P>0.05);观察组生活质量改善情况明显优于对照组,差异有统计学意义(P<0.05)。结论新冠肺炎预防2号方联合胸腺法新治疗晚期NSCLC患者,能增强化疗后机体细胞免疫功能,提高化疗后生活质量。

Objective To investigate the effect of No.2 COVID-19 Prevention Formula combined with thymalfasin on immune function and quality of life in patients with advanced non-small cell lung cancer(NSCLC)after chemotherapy.Methods Patients with advanced NSCLC admitted to our hospital from January 1,2020 to March 15,2020 were randomly divided into observation group(n=50)and control group(n=50).The patients in the two groups were treated with docetaxel combined with cisplatin for chemotherapy.The control group was given subcutaneous injection of thymalfasi,and the observation group was treated with No.2 COVID-19 Prevention Formula on the basis of the control group.One chemotherapy cycle was 21 days,and the treatment lasted for 3 cycles.The changes of T cell subsets,humoral immune indexes,lymphocyte level and quality of life were compared between the two groups before and after treatment.Results After treatment,the level of CD_(4)^(+)and the ratio of CD_(4)^(+)/CD_(8)^(+)in the observation group were significantly higher than those in the control group(P<0.05),but there was no significant difference in the levels of IgG,IgA,IgM,lymphocyte percentage and absolute value between the two groups after treatment(P>0.05),and the improvement of quality of life in the observation group was significantly better than that in the control group(P<0.05).Conclusion COVID-19 Preventive Formula 2 combined with thymus therapy can enhance the cellular immune function and improve the quality of life of patients with advanced NSCLC after chemotherapy.